Dr. Tazeem Shaik is a Consultant Gynecologist at Genesis Fertility and Laparoscopy Centre since Jan 2018. She received her medical degree from Kurnool Medical College and completed her three-year residency in Obstetrics and Gynecology. Dr. Tazeem has come to us with a very strong education and background, having graduated from medical school with honors; and several awards and gold medal for her academic excellence.
Dr. Tazeem Shaik is a Gynecologist and medical scientist with an interest in Reproductive Medicine and Gynaecological Oncology. As a physician, she aimed to improve outcomes for patients through clinical care as well as research. She strongly believes that research is the key to developing better treatments. To this effect, she began this pursuit by joining Medical Scientist Post doctoral Graduate Program in the United States at the Rutgers University – Robert Wood Johnson Medical School, a world-renowned institution. Here, Dr. Tazeem Shaik has worked as a clinical investigator on the development of superior and novel targeted molecular anti cancer drugs against the most common cancers in the United States and worldwide. In 2014 while working in Rutgers Robert Wood University Hospital, United States, she received the “Gold Doc” Certificate and lapel pin from The Arnold P. Gold Foundation, USA. The ‘Gold Doc’ is recognition for humanism in medicine. It is a very distinctive honor to be one among about a hundred physicians recognized nationally by the Foundation, since this award is both a proof and a constant reminder that her skills, experience, and compassion make a remarkable difference in the lives of patients.
She has presented her original research work at several international and national annual scientific meetings. Most of her cancer research findings have been published as priority research papers in Oncotarget, Molecular Biology of the Cell, and Cancer Research which are all leading international medical journals.
She has been invited to judge original research submitted to major international journals in Obstetrics and Gynecology including the American Journal of Obstetrics & Gynecology (AJOG),Obstetrics & Gynecology (The Green Journal), and the BJOG: An International Journal of Obstetrics and Gynecology (BJOG). She is also an editor for the gynecology section of an international Clinical Journal.
Through these activities Dr. Tazeem stays abreast of the most recent and cutting-edge fertility treatments and strives to provide evidence-based medicine to all patients; but at the same timealso recognizes the importance of personalized approach to tailor the treatment options for achieving success in fertility and pregnancy.
Dr. Tazeem Shaik is compassionate and methodical. She believes patients deserve an honest and thorough explanation before embarking on fertility journey together.
Tazeem Shaik, Gulam M. Rather, Nitu Bansal, Tamara Minko, Olga Garbuzenko, Zoltan Szekely,Emine E. Abali, Debabrata Banerjee, John E. Kerrigan, Kathleen W. Scotto, Joseph R. Bertino.(2018). Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lungcancer and prostate cancer. Oncotarget, 9(70), 33249–33257. doi:10.18632/oncotarget.26064
Tazeem Shaik, Nitu Bansal, Nadine Johnson Farley, John Kerrigan, Olga Garbuzenko, TamaraMinko, Emine Abali, Zoltan Szekely, Kathleen Scotto, Debabrata Banerjee, Joseph Bertino.Antitumor studies of an E2f1 promoter sequence binding peptide – penetratin conjugate as amolecule targeting E2f in prostate cancer. In: Proceedings of the 106th Annual Meeting of theAmerican Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA):AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1237. doi:10.1158/1538-7445.AM2015-1237T. Shaik, N. Bansal, N.J. Farley, J. Kerrigan, E.E. Abali, D. Banerjee, J.R. Bertino (2014) Antitumorstudies of Modified L– Penetratin Peptide as a molecule targeting E2F in Prostate Cancer. Mol.Biol. Cell 25, page 222-223. doi:10.1091/mbc.E14-10-1437.
Surasak Puvabanditsin, Melissa February, Tazeem Shaik, Arun Kashyap, Chantal Bruno & RajeevMehta. 2q31.1 microdeletion syndrome: case report and literature review. Clinical Case Reports2015; 3(6): 357–360. doi: 10.1002/ccr3.260
Xie X, Bansal N, Shaik T, Kerrigan JE, Minko T, Garbuzenko O, Abali EE, Johnson-Farley N, BanerjeeD, Scotto KW, Bertino JR. A novel peptide that inhibits E2F transcription and regresses prostatetumor xenografts. Oncotarget. 2014 Feb 28;5(4):901-907.